Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019 /
ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine in relapsed or refractory CLL

13th - 16th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.06.19
Views: 679

Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy

Prof Paolo Ghia speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about results from the ASCEND study testing acalabrutinib against rituximab with idelalisib or bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL) patients.

He reports that acalabrutinib was proven to be more effective than the other two drugs, with the progression-free survival (PFS) improved and the drug was also seen to be better tolerated.

Prof Ghia explains that this shows for the first time, in a randomised study, that monotherapy acalabrutinib can be an improvement on current treatment options.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation